Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07220577 | Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis | PHASE2 | ACTIVE NOT_RECRUITING | 34 | — | — | Nov 10, 2025 | Sep 6, 2027 | May 14, 2026 | 28 | United States, Bulgaria +7 |
To assess the efficacy of GIA632 compared to placebo at week 16
| Arm | Type | Description |
|---|---|---|
| GIA632 | EXPERIMENTAL | Active treatment arm |
| Placebo | PLACEBO_COMPARATOR | Placebo treatment arm |
| Name | Type | Description |
|---|---|---|
| GIA632 | DRUG | Active treatment arm |
| Placebo | OTHER | Placebo treatment arm |
Key Inclusion Criteria: * Able and willing to sign the informed consent form * Patients with a diagnosis of atopic dermatitis and disease for at least 1 year * Moderate to severe atopic dermatitis Key Exclusion Criteria: * Participants with a clinically significant medical condition or infectious...